XIAP overexpressing inflammatory breast cancer patients have high infiltration of immunosuppressive subsets and increased TNFR1 signaling targetable with Birinapant

CONCLUSION: Using immunophenotyping and gene expression analysis in patient biospecimens along with in silico modeling and a preclinical model with a pan-IAP antagonist, this study revealed an interplay between increased TAMs, TNF-α signaling, and XIAP activation during (immune) stress in IBC. These data demonstrate the potential of IAP antagonists as immunomodulators for improving IBC therapeutic regimens.PMID:38412664 | DOI:10.1016/j.tranon.2024.101907

Source: Translational Oncology - February 27, 2024 Category: Cancer & Oncology Authors: Christophe Van Berckelaer Steven Van Laere Seayoung Lee Michael A Morse Joseph Geradts Luc Dirix Mark Kockx Fran çois Bertucci Peter Van Dam Gayathri R Devi Source Type: research